GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enzymotec Ltd (NAS:ENZY) » Definitions » LT-Debt-to-Total-Asset

Enzymotec (Enzymotec) LT-Debt-to-Total-Asset : 0.00 (As of Sep. 2017)


View and export this data going back to 2013. Start your Free Trial

What is Enzymotec LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Enzymotec's long-term debt to total assests ratio for the quarter that ended in Sep. 2017 was 0.00.

Enzymotec's long-term debt to total assets ratio stayed the same from Sep. 2016 (0.00) to Sep. 2017 (0.00).


Enzymotec LT-Debt-to-Total-Asset Historical Data

The historical data trend for Enzymotec's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enzymotec LT-Debt-to-Total-Asset Chart

Enzymotec Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial 0.08 - - - -

Enzymotec Quarterly Data
Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Enzymotec LT-Debt-to-Total-Asset Calculation

Enzymotec's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2016 is calculated as

LT Debt to Total Assets (A: Dec. 2016 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2016 )/Total Assets (A: Dec. 2016 )
=0/146.949
=0.00

Enzymotec's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2017 is calculated as

LT Debt to Total Assets (Q: Sep. 2017 )=Long-Term Debt & Capital Lease Obligation (Q: Sep. 2017 )/Total Assets (Q: Sep. 2017 )
=0/155.542
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Enzymotec  (NAS:ENZY) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.


Enzymotec LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Enzymotec's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Enzymotec (Enzymotec) Business Description

Traded in Other Exchanges
N/A
Address
Enzymotec Ltd is nutritional and food ingredients company. It develops and manufactures nutritional ingredients and medical foods based on proprietary technologies. Its product portfolio includes Infat, K-Real, Enzy PS solutions, Vayacog, Vayarin and Vayaroll. The company has Nutrition and Vaya Pharma reportable segments. It derives majority of its revenues from Nutrition segment. The firm mainly operates in America, Europe, Australia, Asia, and Israel.

Enzymotec (Enzymotec) Headlines

From GuruFocus

Julian Robertson Cuts Half of Stake in Paulson-Backed Company

By Holly LaFon Holly LaFon 07-01-2016

Tiger Management Founder Julian Robertson Ups Stake in Enzymotec

By Kyle Ferguson Kyle Ferguson 12-07-2015

Julian Robertson Adds to Multiple Positions in 3rd quarter

By Tiziano Frateschi Tiziano Frateschi 12-20-2016